Chi-Med Highlights Updated Phase II Savolitinib / Imfinzi® Combination Data in Advanced Papillary Renal Cell Carcinoma at 2020 ASCO Genitourinary Cancers Symposium

by NASDAQ Market News February 10, 2020

NASDAQ Market News
Click here to email author

vTv Therapeutics Announces Positive Results from Part 2 of the Phase 2 Simplici-T1 Study of TTP399, Potential First-in-Class Oral Adjunctive Therapy for Patients with Type 1 Diabetes

Inventiva files a prospectus in the context of the admission to trading of new shares on Euronext Paris

Ads